Clinical Trial Update: A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) [Phase 3]

View source ↗

Summary

This Phase 3 randomized trial compares tacrolimus/methotrexate/ruxolitinib versus post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil as GVHD prop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• METHOTREXATE (METHOTREXATE)
• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Ruxolitinib (ruxolitinib)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Incyte Corporation | Conditions: Graft-versus-host Disease (GVHD) | Phase 3 | Status: RECRUITING